HARTMANN GROUP account plan
Healthcare innovation and improvement
At a glance
HARTMANN GROUP is a German maker of medical and care products (MoliCare, Zetuvit, Sterillium) with FY2025 revenue of EUR 2,449.6 million.
The HARTMANN GROUP, headed by PAUL HARTMANN AG in Heidenheim, Germany (founded 1818), supplies incontinence, wound care and infection prevention products, plus personal care through Kneipp, to hospitals, care homes, pharmacies, the medical-supply trade and home care. It has its own companies in 36 countries and sells in more than 130, with Germany at 31.7% of revenue and EMEA ex-Germany at 58.6%. In FY2025 revenue was EUR 2,449.6 million (+2.2% organic), adjusted EBITDA EUR 276.9 million at an 11.3% margin and group net income EUR 65.8 million. It employed 10,066 people at the end of 2025. Its shares trade on the Open Market of the Frankfurt exchange.
Business units
Incontinence Management
32.1% of FY2025 revenue (EUR 785.8 million)Absorbent products for all degrees of incontinence under the MoliCare brand, plus skin care and absorbent underwear, for care institutions, home care and the self-pay market. Organic growth was 2.8% in 2025 and 2.1% in H1 2026, led by incontinence pants. Led on the Board by Stefan Grote.
Wound Care
25.5% of FY2025 revenue (EUR 623.6 million)Traditional and advanced wound dressings such as Zetuvit, Cosmopor and Atrauman, and Vivano negative-pressure therapy. Growth comes from atraumatic silicone dressings, especially in the US, while reimbursement cuts in France and uncertainty in Germany weighed on 2025 earnings. Board responsibility lies with François Georgelin.
Infection Management
21.9% of FY2025 revenue (EUR 537.6 million)Risk Prevention (sterile component sets, examination gloves, OR drapes and clothing) and Disinfection (Sterillium hand and Bacillol surface disinfectants). It was the fastest-growing segment in H1 2026 at 7.8% organic, mainly in Germany and Switzerland. Led on the Board by CEO Britta Fünfstück.
Complementary Group Divisions
20.5% of FY2025 revenue (EUR 502.6 million)Kneipp personal care and supplements, CMC private-label cosmetics, cotton and baby products, and KOB elastic textiles. Adjusted EBITDA rose to EUR 28.7 million in 2025, but revenue fell 1.0% organically in H1 2026 on lower Kneipp sales.
Strategic priorities
- PLUS2030 strategy
- Grow faster than competitors in market share and margin, aiming for a number 1 or 2 position in Europe in each segment served, with more focus on sales efficiency, new products and structural cost improvements.
- Cost and efficiency programme
- The 2019-2025 Transformation Program contributed about EUR 270 million cumulatively, and about EUR 50 million more is expected in 2026; PLUS2030 adds gains from digitalisation, standardisation and targeted use of artificial intelligence.
- Advanced wound care in the US
- Grow advanced wound care with silicone as the key technology and expand sales in the US outpatient market; Americas revenue grew 12.5% organically in H1 2026.
- Innovation with measurable benefits
- Every new product must show measurable clinical, operational, patient, economic and, where possible, sustainability benefits; R&D spending was EUR 97.4 million in 2025.
- 2026 guidance
- Moderate organic revenue growth and adjusted EBITDA of EUR 270 to 310 million, confirmed in August 2026.
Latest results
In H1 2026 revenue rose to EUR 1,252.0 million from EUR 1,214.0 million, an organic increase of 3.3% with all core segments contributing. Adjusted EBITDA rose by EUR 25.9 million to EUR 151.7 million, lifting the margin to 12.1% from 10.4%, and group net income reached EUR 57.6 million against EUR 18.1 million. Operating cash flow was EUR 126.2 million against EUR 15.7 million. HARTMANN confirmed its 2026 guidance but expects higher material, energy and freight costs from the Iran war to weigh more on the second half, and negative effects in 2027 from German statutory health insurance and long-term care reforms.
Investments and deals
- Production capex
- Capex of EUR 160.4 million in 2025, 56.0% of it in Germany, including production lines in Germany, France and Spain and high-speed wound dressing lines in France and Poland.
- SAP S/4HANA rollout
- The global migration went live in May 2025 across 28 countries, 17 production sites and 104 warehouses, used by more than 5,500 employees.
- Footprint changes
- Wound care production is being relocated to Poland, a Czech plant is closing with 200 people affected, and further investment is planned at the Herbrechtingen plant and warehouse.
- Pierre Cattier divestment
- Kneipp's unprofitable French natural-cosmetics subsidiary was sold in 2025, with a EUR 18.7 million adjustment.
Challenges and risks
- Reimbursement cuts
- Wound care reimbursement restrictions in France since April 2025, unclear German reimbursement of antimicrobial dressings, and the German hospital, statutory health insurance and long-term care reforms.
- Cost inflation
- High material, energy and freight costs, raised further by the Iran war in 2026, can only partly be passed on through prices.
- Price pressure and Asian competition
- Strong competition from Southeast Asia in traditional wound care and high price pressure in examination gloves; hospitals and care homes award contracts to the cheapest bidder.
- Regulatory burden
- EU MDR recertification of thousands of products and up to 150 mandatory EUDAMED fields per product slow innovation, according to the CEO.
- Tariffs and compliance
- 15% US tariffs on EU medical products, and antitrust damage claims against two Spanish subsidiaries with an EUR 11.8 million provision.
What leadership says
“two things that actually contradict each other: cut costs and invest in innovation”
“The biggest danger is to cling too long to what was”
“crisis resilience currently has no priority in healthcare”
“a strategically important step for the digitalisation and optimisation of our company”
Where a supplier can help
- Regulatory data and MDR compliance
- Tied to the regulatory burden challenge: product data management, EUDAMED submission and recertification services for tens of thousands of products.
- AI and process automation
- Tied to the PLUS2030 efficiency goals and the SAP S/4HANA rollout: automation, analytics and AI use cases on the new ERP backbone.
- Energy and freight cost reduction
- Tied to the cost inflation challenge: energy procurement, efficiency and logistics optimisation for plants in Germany, France, Spain, the Czech Republic, Poland and Switzerland.
- US market entry support
- Tied to the US advanced wound care priority and the tariff challenge: distribution, market access and reimbursement services in the US outpatient market.
- Production automation
- Tied to the production capex and Asian price pressure: high-speed lines and automation that keep European plants competitive.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like HARTMANN GROUP?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- HARTMANN GRUPPE Geschäftsbericht 2025 (Annual Report 2025)
- PAUL HARTMANN AG (Heidenheim, founded 1818) heads the HARTMANN GROUP, a leading European supplier of medical and care products (MoliCare, Zetuvit, Cosmopor, Sterillium), with own companies in 36 countries and sales in more than 130 countries; shares trade on the Open Market of the Frankfurt exchange.
- FY2025: revenue EUR 2,449.6 million (+1.7% reported, +2.2% organic); adjusted EBITDA up EUR 15.5 million to EUR 276.9 million, margin 11.3% (2024: 10.9%); group net income fell to EUR 65.8 million (2024: EUR 113.7 million), mainly from the Pierre Cattier sale.
- Four segments: Incontinence Management EUR 785.8 million (32.1%), Wound Care EUR 623.6 million (25.5%), Infection Management EUR 537.6 million (21.9%), Complementary Group Divisions (Kneipp, CMC, KOB) EUR 502.6 million (20.5%).
- Germany is 31.7% of revenue (EUR 775.6 million); EMEA ex-Germany 58.6%; APAC 6.0%; Americas only 3.7% but grew 15.6% organically on silicone wound dressings in the US.
- The 2019-2025 Transformation Program contributed about EUR 270 million cumulatively (over EUR 50 million in 2025, about EUR 50 million more expected in 2026); the new strategy PLUS2030 targets stronger market-share and margin development than competitors, with a focus on sales efficiency, AI and digitalisation.
- Headwinds: reimbursement cuts in French wound care (7-day supply rule since April 2025), unclear German reimbursement of antimicrobial dressings, 15% US tariffs on EU medical products, high material and energy costs, German hospital reform.
- Capex EUR 160.4 million (56.0% in Germany); R&D EUR 97.4 million; global SAP S/4HANA go-live in May 2025 across 28 countries, 17 plants and 104 warehouses; 10,066 employees at year end.
- 2026 guidance: moderate organic growth and adjusted EBITDA of EUR 270 to 310 million; dividend kept at EUR 8.00 per share.
- HARTMANN GRUPPE Halbjahresbericht 2026 (Half-Year Report 2026)
- H1 2026 revenue EUR 1,252.0 million (H1 2025: EUR 1,214.0 million), organic growth 3.3%, with all core segments contributing.
- Adjusted EBITDA EUR 151.7 million, up EUR 25.9 million; adjusted EBITDA margin 12.1% (H1 2025: 10.4%); group net income EUR 57.6 million (H1 2025: EUR 18.1 million).
- Infection Management grew fastest: EUR 289.0 million, +7.8% organic, on hand and surface disinfection, gloves, drapes and CombiSet/MediSet in Germany, Switzerland and Austria.
- Wound Care EUR 323.2 million (+4.4% organic) on advanced atraumatic dressings and the US; Incontinence Management EUR 404.1 million (+2.1%); Complementary Group Divisions EUR 235.6 million (-1.0%, weaker Kneipp).
- Americas grew 12.5% organically, APAC 4.6%, Germany 3.4%, EMEA ex-Germany 2.6%.
- Operating cash flow EUR 126.2 million (H1 2025: EUR 15.7 million); equity ratio 57.4%; net financial position EUR -147.7 million; 9,881 employees (-1.8% since year end, mainly production).
- Higher material, energy and freight costs from the Iran war will weigh more in H2 2026 and can only partly be passed on; 2026 guidance confirmed (moderate organic growth, adjusted EBITDA EUR 270-310 million).
- For 2027 HARTMANN expects negative effects on revenue and earnings from new statutory health insurance rules and the planned long-term care reform.
- Die Hartmann-Strategie: "Kosten senken und in Innovationen investieren" (Schwäbische Post)
- CEO Britta Fünfstück says the Transformation Program she launched in 2019 met its goals: measures add an earnings contribution rising by about EUR 50 million a year, more than offsetting cost increases.
- 2025: organic growth of 2.2% to EUR 2.45 billion revenue and adjusted EBITDA of EUR 276.9 million (+EUR 15.5 million); she concedes growth is below what HARTMANN would like, blaming unilateral reimbursement cuts in France and partly Germany.
- Benchmarks each segment against strong competitors on share and profitability; share gains of 1.8 points in French incontinence (brand Confiance) and 4.4 points in Switzerland.
- Every new product must show five measurable benefits (clinical, operational, patient, economic, and if possible sustainability); new silicone wound dressings grew 19% in the US last year.
- Calls EU bureaucracy (MDR recertification, EUDAMED with up to 150 mandatory fields per product) a brake on innovation and speed; prepared the portfolio for a possible ethanol ban before ECHA gave the green light.
- Closing a Czech plant (200 people affected) to stay competitive with Asian suppliers; Herbrechtingen, the largest plant and warehouse, is an "absolutes Kernstück" and will see further investment.
- PLUS2030 aims at stronger growth than competitors in share and margin and a number 1 or 2 position in Europe in every segment served.
- Hartmann-Gruppe zwischen Systemrelevanz und Preisdruck (Süddeutsche Zeitung Dossier, reprinted on corporate.hartmann.info)
- Company-published reprint of a Süddeutsche Zeitung Dossier article (summer series on resilience) built on statements by CEO Britta Fünfstück on supply security versus price pressure in healthcare.
- Fünfstück: "Krisenresilienz hat im Gesundheitssektor aktuell keine Priorität" (crisis resilience currently has no priority in healthcare); hospitals and care homes award contracts to the cheapest bidder.
- HARTMANN still produces many goods in Germany (Heidenheim, Herbrechtingen: OR gowns, disinfectants) but sources intermediate products from China; diversifying supply chains raises costs that the market does not reward.
- Own resilience measures: diversified supply chains, extra safety stocks, alternative sources and technical emergency provisions down to satellite phones in main warehouses.
- Covid lesson: HARTMANN started mask production at the government's request, but could not keep it after the pandemic because customers would not pay more for local production.
- She criticises contradictory policy, e.g. the planned abolition of a dedicated allowance for care aids that financed disinfectants and masks.
- Her three demands: anchor crisis resilience in public tenders, consistent legislation that considers supply security, and recognition of resilience as a national security interest; targeted incentives instead of more bureaucracy.
Questions about HARTMANN GROUP
What does HARTMANN do?
HARTMANN makes medical and care products, including MoliCare incontinence products, Zetuvit and Cosmopor wound dressings and Sterillium disinfectants, plus Kneipp personal care, for hospitals, care homes, pharmacies and home care.
What is HARTMANN's revenue?
FY2025 revenue was EUR 2,449.6 million with adjusted EBITDA of EUR 276.9 million. H1 2026 revenue was EUR 1,252.0 million.
How many employees does HARTMANN have?
HARTMANN employed 10,066 people at the end of 2025 and 9,881 at 30 June 2026.
What is HARTMANN's strategy?
The PLUS2030 strategy aims to grow faster than competitors in market share and margin and reach a number 1 or 2 position in Europe in each segment, supported by cost efficiency, innovation and AI.
Who leads HARTMANN?
Britta Fünfstück is CEO of PAUL HARTMANN AG, with Oliver Neubrand as CFO; Fritz-Jürgen Heckmann chairs the Supervisory Board.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)